title: Autologous bone marrow transplantation for advanced stage adult lymphoblastic lymphoma in first complete remission. Report of the Non-Hodgkin's Lymphoma Cooperative Study Group (NHLCSG).
abstract: Thirty-six successive adult patients with lymphoblastic lymphoma entered a study of sequential chemotherapy consisting of an intensive LSA2-L2-type protocol to induce first complete remission. Eighteen patients in first CR (median age 22 years, range 15-51), underwent autologous bone marrow transplantation after receiving a conditioning regimen consisting of cyclophosphamide and total body irradiation. Of these 18 patients, 2 were in stage III and 16 in stage IV; 15 showed mediastinal and 9 bone marrow involvement at diagnosis. The transplant procedure was well tolerated and no treatment-induced deaths occurred. At this time, 14 out of 18 patients are alive and well between 1 and 60 months post transplant (median follow-up time 46 months) with an actuarial disease-free survival of 74%. This phase II study suggests that high-dose chemo-radiotherapy followed by autologous bone marrow transplantation may improve long-term disease-free survival in advanced stage adult lymphoblastic lymphoma.
authors.affiliation: Division of Hematology, Ospedale S. Martino, Genoa, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Santini
authors.forename: P
authors.initials: P
authors.lastname: Coser
authors.forename: T
authors.initials: T
authors.lastname: Chisesi
authors.forename: A
authors.initials: A
authors.lastname: Porcellini
authors.forename: R
authors.initials: R
authors.lastname: Sertoli
authors.forename: A
authors.initials: A
authors.lastname: Contu
authors.forename: O
authors.initials: O
authors.lastname: Vinante
authors.forename: A M
authors.initials: AM
authors.lastname: Congiu
authors.forename: A M
authors.initials: AM
authors.lastname: Carella
authors.forename: T
authors.initials: T
authors.lastname: D'Amico
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007945:Leukemia, Lymphoid / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010198:Pancytopenia / Q000209:etiology; D012074:Remission Induction; D015996:Survival Rate; D014916:Whole-Body Irradiation
chemical_list: D003520:Cyclophosphamide